CYP24A1 (25-hydroxyvitamin D-24-hydroxylase) is a useful enzyme target for a range of medical conditions including cancer, cardiovascular and autoimmune disease, which show elevated CYP24A1 levels and corresponding reduction of calcitriol (the biologically active form of vitamin D). A series of (E)-N-(2-(1H-imidazol-1-yl)-2-(phenylethyl)-3/4-styrylbenzamides have been synthesised using an efficient synthetic route and shown to be potent inhibitors of CYP24A1 (IC50 0.11-0.35 M) compared with the standard ketoconazole. Molecular modelling using our CYP24A1 homology model showed the inhibitors to fill the hydrophobic binding site, forming key transition metal interaction between the imidazole nitrogen and the haem Fe 3+ and multiple interactions with the active site amino acid residues. UVB Skin 7-Dehydrocholesterol Previtamin D Vitamin D 3 Complex with binding protein in liver CYP2R liver 25-hydroxyvitamin D 3 Renal tubles Calcitriol Degradation CYP24A1 Calcitroic acid inactive Excreted in urine PTH CYP27B1 = stimulate the action = inhibit the action 4 vitamin D) (Figure 1) 2 . 1,25(OH)2D 3 (calcitriol), the active form of vitamin D, is produced in the renal distal convoluted tubule at position 1α by CYP27B1 a cytochrome P450
Introduction
Vitamin D is the starting compound of an endocrine system, and plays a principal role in the maintenance of calcium and phosphate homeostasis and is essential for the maintenance of a healthy skeleton 1 . Vitamin D is produced in the epidermis from 7-dehydrocholestrol, by sunlight or UV light. Vitamin D can also be obtained from dietary sources. Previtamin D3 is produced by the opening of the steroid nucleus (B ring broken by UV light with spectrum 280 -320 UV β) 2 . Previtamin D3 isomerises into Vitamin D3 3 . Additionally the three most important steps in vitamin D metabolism, 25-hydroxylation, 1 -hydroxylation, and 24-hydroxylation are all performed by cytochrome P450 enzymes 4 . 
Molecular modelling
To investigate the possible binding mode of this series of compounds, we have performed a set of molecular docking simulations, using our model of CYP24A1 24, 30 . We have previously shown the importance of the styrylphenyl structure for inhibitory activity and that the imidazole was essential for metal-ligand interaction with the haem group of the enzyme 23, 24, 25 .
Compounds 11a -11f have electron withdrawing and electron donating substituents on the phenyl ring. All compounds were designed without substitution on styrene group except compound 11f, which has a 4-Cl on the phenyl ring and 3,4-dimethoxy substitution on the styrene group. All the compounds reached the active site through the vitamin D access tunnel and interacted with multiple hydrophobic residues (Arg128, Glu130, Ile131, Trp134, Leu148, Asn208, Phe212, Ile239, Ile242, Lys243, Met246, Ser247, Phe249, Ala326, Val328, Glu329, The330, Val391 and Thr500). Compounds 11b -11d, formed hydrogen bonds between the 10 nitrogen of the amide group with Leu325. For compound 11e an additional hydrogen bond between the methoxy group and Arg128 was observed. The distance between the imidazole ring and the haem iron was between 2.18 Å and 2.58 Å (Table 2) . 
CYP24A1 enzyme inhibition
All the final compounds 11a -11f and 17a -17d were evaluated to determine CYP24A1inhibitory activity. The assay was performed according to the method of Zhu et al 31 and in general, the compounds displayed potent inhibition of CYP24A1 activity when compared with the ketoconazole standard and the lead compound 1 (IC50 0.40 μM) 24 . The IC50 values ranged between 11 and 35 μM with the best IC50 value was obtained for the 3,4dimethoxy styrylbenzamide derivative 11e (0.11 µM) (Table 4 ). Interestingly, the 4-methoxy derivative 11e was also found to interact with the iron of the haem via the methoxy group (distance 2.19 Å), which may contribute to the optimal inhibitory activity in this series of compounds ( Figure 3 ). In general, binding energies (Tables 2 and 3 ) and IC50 showed a good correlation with the exception of compounds 11b and 17c ( Fig.4 ). Substitution of these compounds with the more bulky trifluoromethyl group in the para position of the phenyl ring results in a slightly less favourable conformer energy compared with the other inhibitors, which affects the overall binding energy. 
Conclusions
A series of 3-and 4-styrylbenzamide imidazole derivatives have been prepared using an efficient synthetic route. All the derivatives showed very good inhibitory activity against CYP24A1 and, although there were some small differences in IC50 values depending on substituents, overall both 3-and 4-styrylbenzamide imidazoles and a range of substituents were very well tolerated without any significant loss of inhibitory activity. This inhibitory data would agree with the molecular docking where all the compounds fit well within the active site and showed a good fill of the hydrophobic channel of the CYP24A1 active site as well as transition metal interaction between the iron of the haem and the imidazole ring of the derivatives. Compounds were visualised by illumination under UV light (254 nm) or by the use of vanillin stain followed by charring on a hotplate. Melting points were determined on an electrothermal instrument and are uncorrected. All solvents were dried prior to use and stored over 4Å molecular sieves, under nitrogen. All compounds were more than 95% pure.
Experimental

General procedure for the preparation of (E)-N-(2-(4-substitued-phenyl)-2hydroxyethyl)-4-styrylbenzamides (9) and (E)-N-(2-hydroxy-2-phenylethyl)-3styrylbenzamides (15).
A suspension of (E)-styrylbenzoic acid (8 or 14) (2 mmol) in dry DMF (8 mL) was combined with CDI (2.2 mmol). The reaction was stirred for 1 h at room temperature under nitrogen. The mixture was cooled to 0 °C then added to a solution of 2-amino-1-phenylethan-1-ol (5) (2 mmol) in dry DMF (2.5 mL). The resulting mixture was stirred at room temperature overnight and on completion, ice was added into the flask and a white solid precipitated out. The precipitate was then filtered, washed with ice-cold water and dried. 3.44 (m, 1H, CH2). 13 1.4.5. (E)-N-(2-(1H-imidazol-1-yl)-2-(4-methoxyphenyl) rates in the presence and absence of inhibitors. The assay for each compound was performed in at least duplicate and in triplicate for compounds with good inhibitory properties.
(E)-N-(2-(4-chlorophenyl)-2-hydroxyethyl)-4-styrylbenzamide (9a, R = 4-Cl
Molecular modelling
Docking studies were performed using LeadIT2.1.2 docking program by BioSolve.IT 32 . The important amino acid residues of the active pocket (Gln82, Ile131, Trp134, Met246, Ala326, Glu329, Thr330, Val391, Phe393, Thr394, Ser498, Gly499, Tyr500) 30 were selected and then the selection was extended to 12 Å in order to include in the docking site the haem iron region and the access tunnel to the catalytic site. A ligands database in mol2 format, prepared using MOE 33 , was used as input for the docking calculations. The iron atom of the catalytic site was set as essential pharmacophoric feature. Ligand docking was performed using the default values and no water molecules were considered. Ten output solutions were obtained from each compound and visual inspection in MOE was used to identify the interaction between ligand and protein.
